Assenagon Asset Management S.A. Seagen Inc. Transaction History

Assenagon Asset Management S.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 06, 2023	SELL	$191.51 - $216.16 $1.62 Million - $1.82 Million	-8,441 Reduced 3.61%	225,066 $47.7 Million
Q2 2023 Jul 25, 2023	SELL	$187.64 - $206.25 $63.5 Million - $69.8 Million	-338,289 Reduced 59.16%	233,507 $44.9 Million
Q1 2023 Apr 18, 2023	BUY	$127.59 - $203.08 $69.9 Million - $111 Million	548,223 Added 2325.64%	571,796 $116 Million
Q4 2022 Jan 12, 2023	SELL	$117.37 - $139.17 $8.46 Million - $10 Million	-72,100 Reduced 75.36%	23,573 $3.03 Million
Q3 2022 Oct 27, 2022	SELL	$135.27 - $180.11 $15.7 Million - $20.9 Million	-116,032 Reduced 54.81%	95,673 $13.1 Million

Q2 2022 Jul 27, 2022	BUY	$108.81 - $179.33 $20.7 Million - $34.2 Million	190,697 Added 907.74%	211,705 $37.5 Million
Q1 2022 Apr 25, 2022	SELL	$119.61 - $157.85 $16,506 - $21,783	-138 Reduced 0.65%	21,008 $3.03 Million
Q4 2021 Feb 01, 2022	SELL	$142.57 - $190.86 $1.33 Million - $1.78 Million	-9,351 Reduced 30.66%	21,146 $3.27 Million
Q3 2021 Oct 19, 2021	BUY	$142.45 - $169.82 $2.39 Million - $2.85 Million	16,803 Added 122.7%	30,497 $5.18 Million
Q2 2021 Jul 15, 2021	BUY	$135.08 - $161.1 $1.85 Million - $2.21 Million	13,694 New	13,694 $2.16 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.